“…of action revealed that acquisition, but not expression of IG glucose-CFP was blocked by a DA D1 antagonist administered into the nucleus accumbens, amygdala, medial prefrontal cortex and lateral hypothalamus (Touzani et al, , 2009a(Touzani et al, , 2009b(Touzani et al, , 2010, whereas a DA D1 antagonist administered into these same sites differentially reduced acquisition and expression of fructose-CFP (Amador et al, 2014;Bernal et al, 2008Bernal et al, , 2009Malkusz et al, 2012). In contrast, opioid receptor antagonism with naltrexone failed to affect the acquisition or expression of CFPs in rats produced by IG sucrose or orally-consumed fructose (Azzara et al, 2000;Baker et al, 2004).…”